monoclonal mouse anti hsv 2 ge antibody  (Absolute Biotech Inc)

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Comparison of systemic delivery of FusOn-CD47-luc and FusOn-luc in immune-competent mice pre-immunized with HSV-2 (A) Schematic illustration of the FusOn-series viruses used in this study. The parental FusOn-H2 was generated by replacing the N-terminal domain of the ICP10 gene, which encodes the large subunit of ribonucleotide reductase (RR), with GFP. The locations of glycoprotein C (gC), the terminal repeat long (TR L ) and short (TR S ) regions, and the internal repeats (IR) are indicated. FusOn-luc was constructed by inserting a luciferase gene cassette ( luc ) upstream of the gC locus, whereas FusOn-CD47-luc was generated by fusing the extracellular domain (ECD) of CD47 to gC and inserting the luc cassette at the same position. (B) IVIS imaging of virus distribution following systemic delivery. Balb/c mice were first immunized twice with a gH-deleted infectious single-cycle HSV-2 (DISC-HSV2) before implantation with CT26 tumor cells in the right flank. Once tumors reached approximately 8 mm in diameter, mice received one of the three viruses via tail vein injection at a dose of 2 × 10 6 PFU. Bioluminescence imaging was performed using an IVIS imager on the indicated days post-injection. The locations of the liver and tumor are indicated by red arrows. Representative images from one of five mice in each treatment group are shown.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: Comparison, Generated, Construct, Luciferase, Imaging, Virus, Injection

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Serial passaging of FusOn-CD47-luc in antiviral immune sera enhances viral infectivity despite neutralizing antibodies (A) Comparison of the original FusOn-CD47-luc virus with its derivative, FusOn-P9, which underwent nine passages in the presence of rat-derived anti-HSV-2 sera. A total of 1 × 10 4 PFU of either FusOn-CD47-luc or FusOn-P9 was mixed with human or rat anti-HSV-2 sera (1:5) and incubated at 37°C for 1 h. The mixture was then applied to Vero cell monolayers in 12-well plates, and plaques were counted 48 h later. (B) Comparison of FusOn-CD47-luc with FusOn-P24, a derivative of FusOn-P9 after an additional 19 passages in the presence of a mixture of rat and huma anti-HSV-2 sera. The virus preparation and titration were performed as described in (A). (C) HR49 was obtained from FusOn-P24 after 25 further passages in the presence of a mixture of rat, mouse, and human anti-HSV-2 sera. Six individual plaques were isolated from HR49 and compared with the indicated viruses for infectivity in the presence of a mixture of eight high-titer human anti-HSV-2 sera (1:10). For this assay, 5 × 10 3 PFU were used. ✻ p < 0.01 compared with FusOn-CD47-luc.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: Passaging, Infection, Comparison, Virus, Derivative Assay, Incubation, Titration, Isolation

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Tumor delivery efficiency of FusOn-SD following systemic delivery in vivo (A) Sequential images of one representative mouse from each group (five mice per group) at the indicated time points after systemic administration of FusOn-SD in immune-competent, CT26-tumor-bearing Balb/c mice pre-immunized with HSV-2. The experimental procedure was identical to that in B. (B) Effect of adoptively transferred human anti-HSV-2 sera on the systemic delivery of FusOn-SD to xenografted human tumors. Mpanc-96 human pancreatic cancer cells were implanted in the right flank of immunodeficient mice. Once tumors reached an approximate size of 8 mm in diameter, mice received an adoptive transfer of 100 μL of either a mixture of eight human anti-HSV-2 sera or non-immune sera as a control, followed by tail vein injection of 2 × 10 6 PFU FusOn-SD. Shown are IVIS images taken 48 h after virus administration, with the tumor sites and corresponding bioluminescent signals highlighted by red circles.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: In Vivo, Adoptive Transfer Assay, Control, Injection, Virus

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Comparison of the antitumor effects of FusOn-SD and FusOn-H2 in a xenografted human colon cancer model in immunodeficient mice with or without adoptive transfer of anti-HSV-2 sera Immunodeficient NOD-SCID mice were subcutaneously inoculated with 1 × 10 6 HCT116 human colon cancer cells. Once tumors became palpable, mice received an adoptive transfer of 100 μL of either control sera (A) or anti-HSV-2 immune sera (B), followed by intravenous administration of 2 × 10 6 PFU of either FusOn-SD or FusOn-H2. Tumor size was measured periodically to determine tumor volume. ★ p < 0.05 compared with FusOn-H2 and PBS; p < 0.05 compared with PBS.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: Comparison, Adoptive Transfer Assay, Control

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: In vivo evaluation of the antitumor effect of FusOn-SD in immune syngeneic tumor models in immune-competent animals (A) Evaluation of FusOn-SD in the murine CT26 colon cancer model. Immune-competent Balb/c mice were immunized with HSV-2 before CT26 cells were implanted subcutaneously. Oncolytic viruses were given intratumorally at a dose of 2 × 10 6 PFU. Tumor size was measured at the indicated time points and plotted. ★ p < 0.05 compared with other oncolytic viruses and PBS; p < 0.05 compared with PBS. (B) Evaluation of FusOn-SD in the murine LL/2 lung cancer model. Immune-competent C57BL6 mice were immunized with HSV-2 before LL/2 cells were implanted subcutaneously. When tumor became palpable, 2 × 10 6 PFU of the indicated oncolytic viruses were given via the tail vein, either alone or in combination with CP and/or PD1 mAb (detailed treatment schemes are provided in the section). Tumor size was measured at the indicated time points and plotted. Due to the rapid growth of these two tumor models in the control group, the experiments were terminated early to address ethical concerns for animal welfare. ★ p < 0.05 compared with other treatment groups and PBS; p < 0.05 compared with PBS.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: In Vivo, Control

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Further characterization of FusOn-SD (A) Western blot analysis of gE in virion particles. (A) Purified virions (1 × 10 6 PFU) were lysed to dissociate viral proteins, which were then subjected to SDS-PAGE and western blotting. The gE protein band is indicated by an arrowhead. (B) ELISA detection of gE on purified virion particles. Purified virions (1 × 10 6 PFU) were used to coat a 96-well plate. Anti-HSV-2 gE mAb was applied at two different dilutions. Following washing, an HRP-labeled rabbit anti-mouse secondary antibody (1:1,000) was added, and the signal was quantified using a plate reader. (C) Comparison of virus replication/yield between HR49 isolates (including FusOn-SD) and FusOn-CD47-luc. Vero cells were infected with the viruses at 0.01 PFU/cell. Viruses were harvested at 24 and 48 h post-infection, and the titers were determined by plaque assay.

Article Snippet: Blots were incubated overnight at 4°C with a monoclonal mouse anti-HSV-2 gE antibody (LSBio, Newark, CA) at 1:1000.

Techniques: Western Blot, Purification, SDS Page, Enzyme-linked Immunosorbent Assay, Labeling, Comparison, Virus, Infection, Plaque Assay